6 ms·
Article also talked about Lilly, which is important because they're developing a triple agonist called retatrutide. It's currently in trials, and if it succeeds
by GenerWork 2y ago
Article also talked about Lilly, which is important because they're developing a triple agonist called retatrutide. It's currently in trials, and if it succeeds, you'll see Novo stock fall even further while Lilly stock will soar.
- loeg 2y agoFWIW it doesn't seem to be much more effective than tirzepatide: > Lilly is also working on a next-generation medicine, called retatrutide, which helped people lose up to about 24% of their weight in a mid-sized study last year. (Tirzepatide saw 22 or 23%.) Unclear to me if or how the retatrutide numbers might improve.
- GenerWork 2y agoI'd bet that it'll exceed tirzepatide by a bit, but they'll hype up the triple agonist action. What's wild is that there's companies doing research for quadruple agonists! Found this[0] company that's looking at one such agonist right now. [0] https://www.biomedind.com/NA-931.html https://www.biomedind.com/NA-931.html